Insulin Analog Marketing
John explains how insulin analogs are marketed to type 2 diabetics in the US despite there being no evidence that they are superior to the cheaper recombinant human insulin. He also discusses how health technology assessment agencies in other countries recommend starting patients on the cheaper insulin. Jordan and John also discuss how insurance co-pay managers can distort the market and lead to less effective treatments.In this clip
From this podcast
The Jordan Harbinger Show
709: John Abramson | How Big Pharma Broke American Health Care
Related Questions